LT3034608T - Pelės, ekspresuojančios imunoglobulino hibridinę lengvąją grandinę, turinčią žmogaus kintamąją sritį - Google Patents

Pelės, ekspresuojančios imunoglobulino hibridinę lengvąją grandinę, turinčią žmogaus kintamąją sritį

Info

Publication number
LT3034608T
LT3034608T LTEP16154526.4T LT16154526T LT3034608T LT 3034608 T LT3034608 T LT 3034608T LT 16154526 T LT16154526 T LT 16154526T LT 3034608 T LT3034608 T LT 3034608T
Authority
LT
Lithuania
Prior art keywords
light chain
variable region
human variable
mice expressing
hybrid light
Prior art date
Application number
LTEP16154526.4T
Other languages
English (en)
Lithuanian (lt)
Inventor
Lynn Macdonald
Sean Stevens
Cagan Gurer
Andrew J. Murphy
Karolina A. Hosiawa
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of LT3034608T publication Critical patent/LT3034608T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Position Input By Displaying (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
LTEP16154526.4T 2010-06-22 2011-06-22 Pelės, ekspresuojančios imunoglobulino hibridinę lengvąją grandinę, turinčią žmogaus kintamąją sritį LT3034608T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35731410P 2010-06-22 2010-06-22
US35731710P 2010-06-22 2010-06-22

Publications (1)

Publication Number Publication Date
LT3034608T true LT3034608T (lt) 2019-05-27

Family

ID=44509861

Family Applications (4)

Application Number Title Priority Date Filing Date
LTEP12195716.1T LT2568049T (lt) 2010-06-22 2011-06-22 Pelė, ekspresuojanti imunoglobulino hibridinę lengvąją grandinę su žmogaus kintama sritimi
LTEP14198318.9T LT2905338T (lt) 2010-06-22 2011-06-22 Transgeninė pelė su modifikuotu endogeniniu lambda imunoglobulino lokusu
LTEP16154526.4T LT3034608T (lt) 2010-06-22 2011-06-22 Pelės, ekspresuojančios imunoglobulino hibridinę lengvąją grandinę, turinčią žmogaus kintamąją sritį
LTEP11728508.0T LT2480675T (lt) 2010-06-22 2011-06-22 Pelė, ekspresuojanti lengvąją grandinę su žmogaus liambda kintama ir pelės pastoviąja sritimis

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LTEP12195716.1T LT2568049T (lt) 2010-06-22 2011-06-22 Pelė, ekspresuojanti imunoglobulino hibridinę lengvąją grandinę su žmogaus kintama sritimi
LTEP14198318.9T LT2905338T (lt) 2010-06-22 2011-06-22 Transgeninė pelė su modifikuotu endogeniniu lambda imunoglobulino lokusu

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP11728508.0T LT2480675T (lt) 2010-06-22 2011-06-22 Pelė, ekspresuojanti lengvąją grandinę su žmogaus liambda kintama ir pelės pastoviąja sritimis

Country Status (30)

Country Link
US (22) US9012717B2 (OSRAM)
EP (7) EP2568049B1 (OSRAM)
JP (16) JP5988969B2 (OSRAM)
KR (16) KR102506001B1 (OSRAM)
CN (4) CN103068994B (OSRAM)
AU (1) AU2011271046B2 (OSRAM)
BR (3) BR122020013427B1 (OSRAM)
CA (2) CA2803864C (OSRAM)
CY (5) CY1117537T1 (OSRAM)
DK (5) DK2480676T3 (OSRAM)
ES (5) ES2646052T3 (OSRAM)
HR (5) HRP20160794T1 (OSRAM)
HU (5) HUE036597T2 (OSRAM)
IL (12) IL313063A (OSRAM)
LT (4) LT2568049T (OSRAM)
ME (5) ME02902B (OSRAM)
MX (6) MX2012015298A (OSRAM)
MY (6) MY157477A (OSRAM)
NO (1) NO2905338T3 (OSRAM)
NZ (6) NZ707200A (OSRAM)
PL (5) PL2480676T3 (OSRAM)
PT (5) PT2480676E (OSRAM)
RS (5) RS55042B1 (OSRAM)
RU (3) RU2601297C2 (OSRAM)
SG (4) SG10201504324UA (OSRAM)
SI (5) SI3034608T1 (OSRAM)
SM (5) SMT201700506T1 (OSRAM)
TR (1) TR201905992T4 (OSRAM)
WO (2) WO2011163311A1 (OSRAM)
ZA (5) ZA201300063B (OSRAM)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
KR102362774B1 (ko) * 2008-09-30 2022-02-15 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
US20110314563A1 (en) 2008-12-18 2011-12-22 Kingdon Craig R Antibody production
NO2792236T3 (OSRAM) 2009-07-08 2018-04-14
US9445581B2 (en) * 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
PL3095871T3 (pl) 2010-02-08 2019-10-31 Regeneron Pharma Mysz zawierająca wspólny łańcuch lekki
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
ES2641920T3 (es) 2010-03-31 2017-11-14 Ablexis, Llc Ingeniería genética de animales no humanos para la producción de anticuerpos quiméricos
ME02902B (me) * 2010-06-22 2018-04-20 Regeneron Pharma Transgeni miševi sa modifikovanim lokusom endogenog lambda imunoglobulina
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
DK2597945T3 (da) 2010-07-26 2020-09-21 Trianni Inc Transgene dyr og fremgangsmåder til anvendelse deraf
RS55495B1 (sr) 2010-08-02 2017-04-28 Regeneron Pharma Miševi koji stvaraju vezujuće proteine koji sadrže vl domene
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
EP2758535B1 (en) 2011-09-19 2016-11-09 Kymab Limited Antibodies, variable domains&chains tailored for human use
EP3741862A1 (en) 2011-09-19 2020-11-25 Kymab Limited Animals, repertoires & methods for the production of human antibodies
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
BR112014015238B1 (pt) 2011-12-20 2022-11-16 Regeneron Pharmaceuticals, Inc Método ex vivo para preparar um anticorpo que se liga a um antígeno de interesse compreendendo identificar sequências de ácido nucleico a partir de linfócitos b de camundongo geneticamente modificado pela colocação de um gene adam6
LT2883449T (lt) 2012-03-16 2018-05-10 Regeneron Pharmaceuticals, Inc. Histidinu modifikuoti lengvosios grandinės antikūnai ir juos gaminantys genetiškai modifikuoti graužikai
CN106318951A (zh) 2012-03-16 2017-01-11 瑞泽恩制药公司 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
EP3539374A1 (en) 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
EP2831245A1 (en) 2012-03-28 2015-02-04 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
EP2840892B1 (en) 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
ES2942413T3 (es) * 2013-03-13 2023-06-01 Regeneron Pharma Ratones que expresan un repertorio limitado de cadenas ligeras de inmunoglobulina
ES2829376T3 (es) 2013-03-14 2021-05-31 Univ Erasmus Med Ct Rotterdam Mamífero no humano transgénico para la producción de anticuerpos
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) * 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
KR20200103882A (ko) * 2013-09-18 2020-09-02 리제너론 파마슈티칼스 인코포레이티드 히스티딘 엔지니어링된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-인간 동물
SG11201602236SA (en) 2013-10-01 2016-04-28 Kymab Ltd Animal models and therapeutic molecules
TW201532513A (zh) * 2014-01-10 2015-09-01 Alfur Fu-Hsin Hung 能產生比小鼠ＩgＥ量高出許多的人源化ＩgＥ之基因轉殖動物
RU2016141123A (ru) 2014-03-21 2018-04-23 Регенерон Фармасьютикалз, Инк. Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики
JP6636498B2 (ja) 2014-03-21 2020-01-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 単一ドメイン結合タンパク質を作る非ヒト動物
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
US20160081314A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
WO2016054598A2 (en) 2014-10-03 2016-04-07 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
ES2807182T3 (es) 2014-11-21 2021-02-22 Bristol Myers Squibb Co Anticuerpos frente a CD73 y sus usos
KR102582807B1 (ko) 2014-12-19 2023-09-26 레제네상스 비.브이. 인간 c6에 결합하는 항체 및 이의 용도
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
PT3254035T (pt) 2015-02-05 2019-05-13 Basf Se Central de energia solar com um primeiro circuito de transferência de calor e um segundo circuito de transferência de calor
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
RS63897B1 (sr) 2015-05-29 2023-02-28 Bristol Myers Squibb Co Antitela protiv ox40 i njihova primena
CA2990015A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
EP3411476B1 (en) 2016-02-04 2024-04-24 Trianni, Inc. Enhanced production of immunoglobulins
ES2985566T3 (es) 2016-03-04 2024-11-06 Univ Rockefeller Anticuerpos contra CD40 con actividad agonista mejorada
SG10201913033UA (en) 2016-03-04 2020-03-30 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
WO2017196663A1 (en) 2016-05-09 2017-11-16 Bristol-Myers Squibb Company Tl1a antibodies and uses thereof
NZ747857A (en) 2016-05-20 2023-01-27 Regeneron Pharma Methods for breaking immunological tolerance using multiple guide rnas
RS66700B1 (sr) 2016-06-03 2025-05-30 Regeneron Pharma Glodari koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
US10650241B2 (en) * 2016-06-27 2020-05-12 Facebook, Inc. Systems and methods for identifying matching content
EP4512829A3 (en) 2016-07-14 2025-06-11 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
SG10201912925SA (en) 2016-10-13 2020-02-27 Massachusetts Inst Technology Antibodies that bind zika virus envelope protein and uses thereof
JP6868250B2 (ja) 2016-10-31 2021-05-12 国立大学法人鳥取大学 ヒト抗体産生非ヒト動物及びそれを用いたヒト抗体作製法
DK4082334T3 (da) * 2016-11-04 2025-06-02 Regeneron Pharma Ikke humane dyr med et modificeret immunglobulin-lambda-letkædelocus
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
WO2019113065A1 (en) * 2017-12-05 2019-06-13 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
WO2019140229A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
TW202003565A (zh) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 抗mica及/或micb抗體及其用途
EP3772927B1 (en) 2018-03-24 2025-01-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
CA3093850A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
WO2019236670A1 (en) * 2018-06-08 2019-12-12 Crystal Bioscience Inc. Transgenic animal for producing diversified antibodies that have the same light chain i
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
EP3872506A4 (en) 2018-10-26 2023-01-11 Vehicle Energy Japan Inc. BATTERY MONITORING DEVICE
PE20211284A1 (es) 2018-11-16 2021-07-19 Bristol Myers Squibb Co Anticuerpos anti-nkg2a y usos de los mismos
CN113396162B (zh) 2019-01-22 2024-08-16 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
SG11202107589PA (en) 2019-02-22 2021-08-30 Regeneron Pharma Rodents having genetically modified sodium channels and methods of use thereof
US20220330532A1 (en) * 2019-06-05 2022-10-20 Regeneron Pharmaceuticals, Inc. Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
EP3993623B1 (en) * 2019-07-01 2025-02-19 Trianni, Inc. Transgenic rodents and methods of use thereof
JP7726881B2 (ja) 2019-12-02 2025-08-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
JP2023541216A (ja) * 2020-06-25 2023-09-29 ヒューマブ カンパニー リミテッド ヘテロ接合型トランスジェニック動物
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Ｆｃアルファ受容体を発現するマウス
US12371475B2 (en) 2020-12-23 2025-07-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
IL303865A (en) 2020-12-23 2023-08-01 Regeneron Pharma Methods for obtaining antibodies that bind transmembrane proteins and cells that produce them
WO2023199655A1 (ja) 2022-04-13 2023-10-19 日本精工株式会社 軸受装置の状態の検出方法、検出装置、およびプログラム
USD999969S1 (en) * 2022-04-29 2023-09-26 Shenzhen Intellirocks Tech. Co., Ltd. Lamp
EP4658687A1 (en) 2023-01-31 2025-12-10 University of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
CN121079326A (zh) 2023-05-04 2025-12-05 诺瓦森塔股份有限公司 抗cd161抗体及其使用方法
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
CA2722378C (en) * 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) * 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
US7476536B2 (en) * 2001-05-11 2009-01-13 Kirin Pharma Kabushiki Kaisha Artificial human chromosome containing human antibody a light chain gene
GB0115256D0 (en) * 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
ES2645563T3 (es) 2001-11-30 2017-12-05 Amgen Fremont Inc. Animales transgénicos que portan genes de cadena ligera de Ig humana
US20030217171A1 (en) 2002-05-17 2003-11-20 Von Stuermer Wolfgang R. Self-replicating and self-installing software apparatus
CN103205436B (zh) * 2003-07-15 2016-05-25 人类多克隆治疗公司 人源化免疫球蛋白基因座
CN1605628A (zh) * 2003-09-03 2005-04-13 中国疾病预防控制中心病毒病预防控制所 Cho细胞生产的人源抗甲肝病毒基因工程抗体
PT1773885E (pt) * 2004-08-05 2010-07-21 Genentech Inc Antagonistas anti-cmet humanizados
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
CN101111521B (zh) * 2004-12-29 2011-08-24 株式会社柳韩洋行 肿瘤坏死因子-α特异性人源化抗体
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
JP2010501165A (ja) * 2006-08-22 2010-01-21 ジーツー インフラメイション プロプライエタリー リミテッド 抗体の作製方法
MX2009003393A (es) 2006-10-02 2009-05-11 Regeneron Pharma Anticuerpos humanos de alta afinidad para el receptor de il-4 humano.
US7864492B2 (en) 2006-10-31 2011-01-04 Siemens Industry, Inc. Systems and methods for arc fault detection
DE102007045897A1 (de) 2007-09-26 2009-04-09 Carl Zeiss Microimaging Gmbh Verfahren zur mikroskopischen dreidimensionalen Abbildung einer Probe
EP2271758B1 (en) * 2008-04-14 2018-09-12 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
EP2669298A3 (en) 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
KR102362774B1 (ko) 2008-09-30 2022-02-15 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
US20110314563A1 (en) * 2008-12-18 2011-12-22 Kingdon Craig R Antibody production
NO2792236T3 (OSRAM) * 2009-07-08 2018-04-14
PL3095871T3 (pl) * 2010-02-08 2019-10-31 Regeneron Pharma Mysz zawierająca wspólny łańcuch lekki
CN105695415A (zh) 2010-06-17 2016-06-22 科马布有限公司 动物模型及治疗分子
ME02902B (me) 2010-06-22 2018-04-20 Regeneron Pharma Transgeni miševi sa modifikovanim lokusom endogenog lambda imunoglobulina

Also Published As

Publication number Publication date
KR102266097B1 (ko) 2021-06-18
PT2905338T (pt) 2017-11-10
HRP20160865T1 (hr) 2016-10-07
AU2011271046B2 (en) 2015-10-01
JP6073441B2 (ja) 2017-02-01
CA2804311C (en) 2017-09-12
AU2011271043A8 (en) 2016-01-21
KR20190049932A (ko) 2019-05-09
NZ707200A (en) 2016-04-29
KR20190073584A (ko) 2019-06-26
ES2576928T3 (es) 2016-07-12
MY157477A (en) 2016-06-15
US20160060359A1 (en) 2016-03-03
MY195217A (en) 2023-01-11
SG186390A1 (en) 2013-01-30
US9844212B2 (en) 2017-12-19
CY1117537T1 (el) 2017-04-26
NZ605758A (en) 2014-08-29
JP2018201528A (ja) 2018-12-27
IL244450A0 (en) 2016-04-21
US10266803B2 (en) 2019-04-23
US20180064078A1 (en) 2018-03-08
TR201905992T4 (tr) 2019-05-21
EP2480675B1 (en) 2016-04-06
KR101975884B1 (ko) 2019-05-10
KR20190014576A (ko) 2019-02-12
RU2016119423A (ru) 2018-11-07
KR101934852B1 (ko) 2019-01-04
US20120070861A1 (en) 2012-03-22
LT2905338T (lt) 2017-12-27
US9850462B2 (en) 2017-12-26
JP2016010415A (ja) 2016-01-21
US9399683B2 (en) 2016-07-26
US20130326647A1 (en) 2013-12-05
EP2480676A1 (en) 2012-08-01
JP2017012204A (ja) 2017-01-19
SG10201504568YA (en) 2015-07-30
BR122020013427B1 (pt) 2021-08-03
SMT201900241T1 (it) 2019-05-10
JP2016010417A (ja) 2016-01-21
PT3034608T (pt) 2019-05-28
SMT201600229B (OSRAM) 2016-08-31
KR102211911B1 (ko) 2021-02-05
PT2480676E (pt) 2016-06-09
PL3034608T3 (pl) 2019-08-30
JP2021061863A (ja) 2021-04-22
IL255179B (en) 2018-06-28
ME02440B (me) 2016-09-20
AU2011271043B2 (en) 2015-10-01
SMT201700506T1 (it) 2018-01-11
DK2568049T3 (en) 2016-08-01
CN104342455B (zh) 2017-05-31
EP3034608A1 (en) 2016-06-22
WO2011163311A1 (en) 2011-12-29
IL259965A (en) 2018-07-31
KR102462042B1 (ko) 2022-11-03
KR20180135997A (ko) 2018-12-21
JP2025027148A (ja) 2025-02-26
MY165287A (en) 2018-03-21
US9206261B2 (en) 2015-12-08
PL2480676T3 (pl) 2016-10-31
SI2480676T1 (sl) 2016-10-28
KR20210013376A (ko) 2021-02-03
JP2013531501A (ja) 2013-08-08
MY195214A (en) 2023-01-11
KR20200064166A (ko) 2020-06-05
IL223719A (en) 2016-10-31
KR20200143511A (ko) 2020-12-23
US9035128B2 (en) 2015-05-19
ME02902B (me) 2018-04-20
US9226484B2 (en) 2016-01-05
HK1226766A1 (en) 2017-10-06
DK2480675T3 (en) 2016-08-01
EP2905338B1 (en) 2017-08-02
IL247386A (en) 2017-07-31
US20140137275A1 (en) 2014-05-15
AU2011271043A1 (en) 2013-01-31
US20190203171A1 (en) 2019-07-04
US9163092B2 (en) 2015-10-20
JP5988969B2 (ja) 2016-09-07
NZ626979A (en) 2015-05-29
HRP20171666T1 (hr) 2017-12-15
EP3456832A1 (en) 2019-03-20
HRP20190807T1 (hr) 2019-08-23
SG186391A1 (en) 2013-01-30
CY1122877T1 (el) 2021-05-05
EP2905338B8 (en) 2018-01-24
SI2480675T1 (sl) 2016-08-31
ME03386B (me) 2020-01-20
MY195212A (en) 2023-01-11
IL223720A (en) 2017-05-29
US20150246976A1 (en) 2015-09-03
HK1170766A1 (zh) 2013-03-08
KR20230036157A (ko) 2023-03-14
SI2568049T1 (sl) 2016-10-28
US9206262B2 (en) 2015-12-08
PL2905338T3 (pl) 2018-01-31
ES2721749T3 (es) 2019-08-05
HK1168384A1 (zh) 2012-12-28
HUE044001T2 (hu) 2019-09-30
MX336344B (es) 2016-01-15
US9394373B2 (en) 2016-07-19
HUE029691T2 (en) 2017-03-28
DK2480676T3 (en) 2016-06-20
CN103068993A (zh) 2013-04-24
IL313063A (en) 2024-07-01
CY1117692T1 (el) 2017-05-17
RS54891B1 (sr) 2016-10-31
JP6545773B2 (ja) 2019-07-17
US20170258059A1 (en) 2017-09-14
IL269078A (en) 2019-11-28
MX2022002117A (es) 2022-03-17
US20150176002A1 (en) 2015-06-25
US9540452B2 (en) 2017-01-10
MX347318B (es) 2017-04-21
KR102059909B1 (ko) 2019-12-27
SG10201504324UA (en) 2015-07-30
JP2017006152A (ja) 2017-01-12
MX347322B (es) 2017-04-21
ES2646052T3 (es) 2017-12-11
HUE029692T2 (en) 2017-03-28
NZ707198A (en) 2016-04-29
KR20130121814A (ko) 2013-11-06
LT2568049T (lt) 2016-10-10
CY1119478T1 (el) 2018-03-07
US9066502B2 (en) 2015-06-30
RS55037B1 (sr) 2016-12-30
CA2804311A1 (en) 2011-12-29
AU2011271043A9 (en) 2015-10-01
US20150351371A1 (en) 2015-12-10
KR102193823B1 (ko) 2020-12-22
MX2012015298A (es) 2013-05-01
US9206263B2 (en) 2015-12-08
MY194456A (en) 2022-11-30
US9150662B2 (en) 2015-10-06
IL259965B (en) 2019-02-28
IL300712B2 (en) 2024-11-01
MX2012015300A (es) 2013-05-01
IL244450A (en) 2017-11-30
NZ605751A (en) 2014-10-31
KR101970944B1 (ko) 2019-04-23
KR20220150430A (ko) 2022-11-10
ZA201404600B (en) 2015-09-30
EP2480676B1 (en) 2016-04-06
US9006511B2 (en) 2015-04-14
IL291301A (en) 2022-05-01
ME02444B (me) 2016-09-20
CN104404050A (zh) 2015-03-11
BR112012032991A2 (pt) 2015-10-06
EP2480675A1 (en) 2012-08-01
JP6009441B2 (ja) 2016-10-19
KR102320944B1 (ko) 2021-11-04
SI3034608T1 (sl) 2019-06-28
ES2575223T3 (es) 2016-06-27
IL264634B (en) 2019-09-26
JP6243384B2 (ja) 2017-12-06
IL269078B (en) 2021-05-31
IL282872B (en) 2022-04-01
JP2018201527A (ja) 2018-12-27
RU2013102595A (ru) 2014-07-27
US9029628B2 (en) 2015-05-12
US20190153384A1 (en) 2019-05-23
US20130323790A1 (en) 2013-12-05
CY1118126T1 (el) 2017-06-28
KR20210134424A (ko) 2021-11-09
ZA201300063B (en) 2014-09-25
IL291301B1 (en) 2023-03-01
ZA201300062B (en) 2014-09-25
EP3034608B1 (en) 2019-01-30
IL300712A (en) 2023-04-01
CN104404050B (zh) 2018-06-08
IL291301B2 (en) 2023-07-01
CN104342455A (zh) 2015-02-11
KR101991234B1 (ko) 2019-06-20
PL2568049T3 (pl) 2017-03-31
KR20180135996A (ko) 2018-12-21
EP2568049B1 (en) 2016-04-13
RS58736B1 (sr) 2019-06-28
ME02442B (me) 2016-09-20
JP6341972B2 (ja) 2018-06-13
KR101945352B1 (ko) 2019-02-07
SI2905338T1 (sl) 2017-12-29
KR102506001B1 (ko) 2023-03-07
US20120073004A1 (en) 2012-03-22
JP6963542B2 (ja) 2021-11-10
HK1183321A1 (en) 2013-12-20
RU2016119423A3 (OSRAM) 2019-11-19
JP2019033765A (ja) 2019-03-07
BR112012032991A8 (pt) 2020-09-29
IL255179A0 (en) 2017-12-31
DK3034608T3 (da) 2019-05-06
US20150089680A1 (en) 2015-03-26
RS56589B1 (sr) 2018-02-28
US20200239837A1 (en) 2020-07-30
KR102001430B1 (ko) 2019-07-18
RS55042B1 (sr) 2016-12-30
ES2570131T3 (es) 2016-05-17
US20160057979A1 (en) 2016-03-03
JP2013532974A (ja) 2013-08-22
JP2022066449A (ja) 2022-04-28
JP2018023403A (ja) 2018-02-15
CN103068993B (zh) 2016-01-06
NZ627119A (en) 2015-05-29
KR20210073609A (ko) 2021-06-18
US20150173332A1 (en) 2015-06-25
CN103068994A (zh) 2013-04-24
SMT201600212B (it) 2016-08-31
AU2011271046A1 (en) 2013-01-31
EP3205726A1 (en) 2017-08-16
JP2020128440A (ja) 2020-08-27
KR20190142436A (ko) 2019-12-26
PL2480675T3 (pl) 2017-03-31
PT2568049T (pt) 2016-07-11
EP2905338A1 (en) 2015-08-12
DK2905338T3 (da) 2017-11-06
NO2905338T3 (OSRAM) 2017-12-30
LT2480675T (lt) 2016-10-10
BR112012033248A2 (pt) 2017-11-28
RU2601297C2 (ru) 2016-10-27
KR20130027555A (ko) 2013-03-15
JP7236409B2 (ja) 2023-03-09
ZA201404601B (en) 2016-02-24
US20150246977A1 (en) 2015-09-03
US9012717B2 (en) 2015-04-21
EP2568049A1 (en) 2013-03-13
JP2023133554A (ja) 2023-09-22
HRP20160794T1 (hr) 2016-08-12
HUE030285T2 (en) 2017-05-29
KR102118565B1 (ko) 2020-06-03
HUE036597T2 (hu) 2018-07-30
CN103068994B (zh) 2016-01-20
RU2724736C2 (ru) 2020-06-25
IL300712B1 (en) 2024-07-01
RU2013102596A (ru) 2014-07-27
CA2803864A1 (en) 2011-12-29
US20150173331A1 (en) 2015-06-25
ZA201506598B (en) 2017-03-29
HRP20160497T1 (hr) 2016-07-15
MX348942B (es) 2017-07-04
JP2020062061A (ja) 2020-04-23
US20170107484A1 (en) 2017-04-20
KR20190014578A (ko) 2019-02-12
US20150320023A1 (en) 2015-11-12
SMT201600213B (it) 2016-08-31
RU2590594C2 (ru) 2016-07-10
US9334333B2 (en) 2016-05-10
CA2803864C (en) 2017-05-16
BR112012032991B1 (pt) 2021-08-10
US20240327785A1 (en) 2024-10-03
WO2011163314A1 (en) 2011-12-29
PT2480675T (pt) 2016-07-11
IL282872A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
HRP20160865T1 (hr) Miš koji izražava hibridni laki lanac imunoglobulina s humanom varijabilnom regijom
IL266268B (en) Mice with humanized light chain
SG11201405058WA (en) Animals expressing human lambda immunoglobulin light chain variable domain
ZA201505835B (en) Mice expressing a limited immunoglobulin light chain reperoire
DE102010034562B8 (de) Operationsleuchte mit verbesserter Bedienungsfunktionalität
PL2384180T3 (pl) Powłoka pieluchy
GB2481036B (en) A vehicle light and a vehicle including at least one vehicle light
GB201004506D0 (en) Light snack
PT2384180E (pt) Capa de fralda
GB201019977D0 (en) Bi-specific immunoglobulins